Esophageal cancer (EC) consists of tumors with a generally poor prognosis, and treatment options for patients with disease recurrence are extremely limited. Due to this poor patient prognosis, the possible treatment toxicity should be carefully balanced against its potential benefit and patient quality of life. Stereotactic body radiotherapy (SBRT) is a rapidly expanding novel technique combining a short treatment time together with high local efficacy and an acceptable toxicity profile. There are no publications thus far presenting data regarding the usage of SBRT utilizing a conventional linear accelerator in locally recurrent EC patients. In the present study, 2 patients with recurrent EC in the neck lymph nodes were treated by SBRT in the Department of Oncology, University Hospital Olomouc, Czech Republic. The treatment dose was 30 and 40 Gy in 5 daily fractions, with a prescribed dose to 65 and 81% isodose, for each patient respectively, utilizing a volumetric arc therapy technique, a 6-MV photon beam and an Elekta Synergy linear accelerator. The treatment was delivered without any unintentional treatment interruptions and without any treatment-related acute toxicity. The maximum dose in the patients was 45.9 and 49.2 Gy, respectively. The maximum doses for the surrounding major blood vessels were 35.4 and 45.7 Gy, respectively. Maximum doses to the trachea and the esophagus in the first patient were 32.6 and 27.0 Gy. In the second patient, these doses were not clinically significant. SBRT utilizing linear accelerators should be considered in patients with localized recurrent EC, offering the patients the chance for local control with minimal treatment toxicity.

Department of Oncology Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Department of Surgery Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University University Hospital Olomouc 779 00 Olomouc Czech Republic

Toxicogenomics Unit National Institute of Public Health 100 42 Prague Czech Republic

Zobrazit více v PubMed

Koshy M, Greenwald BD, Hausner P, Krasna MJ, Horiba N, Battafarano RJ, Burrows W, Suntharalingam M. Outcomes after trimodality therapy for esophageal cancer: The impact of histology on failure patterns. Am J Clin Oncol. 2011;34:259–264. doi: 10.1097/COC.0b013e3181e841ce. PubMed DOI

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–1627. doi: 10.1001/jama.281.17.1623. PubMed DOI

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174. doi: 10.1200/JCO.20.5.1167. PubMed DOI

Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098. doi: 10.1016/S1470-2045(15)00040-6. PubMed DOI

Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084. doi: 10.1056/NEJMoa1112088. PubMed DOI

Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–1092. doi: 10.1200/JCO.2007.12.9593. PubMed DOI PMC

Hoeppner J, Zirlik K, Brunner T, Bronsert P, Kulemann B, Sick O, Marjanovic G, Hopt UT, Makowiec F. Multimodal treatment of locally advanced esophageal adenocarcinoma: Which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients. J Surg Oncol. 2014;109:287–293. doi: 10.1002/jso.23498. PubMed DOI

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86. doi: 10.1016/S1470-2045(13)70549-7. PubMed DOI

Laskar SG, Lewis S, Agarwal JP, Mishra S, Mehta S, Patil P. Combined brachytherapy and external beam radiation: An effective approach for palliation in esophageal cancer. J Contemp Brachytherapy. 2015;7:453–461. doi: 10.5114/jcb.2015.56765. PubMed DOI PMC

Rabenstein T. Palliative endoscopic therapy of esophageal cancer. Viszeralmedizin. 2015;31:354–359. doi: 10.1159/000441175. PubMed DOI PMC

Kim YS, Lee CG, Kim KH, Kim T, Lee J, Cho Y, Koom WS. Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiat Oncol J. 2012;30:182–188. doi: 10.3857/roj.2012.30.4.182. PubMed DOI PMC

Ilson DH. Esophageal cancer chemotherapy: Recent advances. Gastrointest Cancer Res. 2008;2:85–92. PubMed PMC

Crane CH. Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. J Radiat Res. 2016;57:i53–i57. doi: 10.1093/jrr/rrw016. (Suppl 1) PubMed DOI PMC

Pontoriero A, Iatì G, Aiello D, Pergolizzi S. Stereotactic radiotherapy in the retreatment of recurrent cervical cancers, assessment of toxicity, and treatment response: Initial results and literature review. Technol Cancer Res Treat. 2016;15:759–765. doi: 10.1177/1533034615608740. PubMed DOI

Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index. J Neurosurg. 2006;105:S194–S201. (Suppl) PubMed

International Commission on Radiation Units and Measurements, corp-author. Prescribing, Recording and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) (ICRU Report 83) J ICRU. 2010;10:1–10618.

Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM Classification Of Malignant Tumours. 7th. Wiley-Blackwell; 2009. pp. 62–66.

Mizota A, Shitara K, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Muro K. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology. 2011;81:237–242. doi: 10.1159/000334057. PubMed DOI

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. doi: 10.1016/S1470-2045(14)70420-6. PubMed DOI

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. PubMed DOI

Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D, et al. Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB (Oxford) 2016;18:88–97. doi: 10.1016/j.hpb.2015.07.007. PubMed DOI PMC

Matzenauer M, Vrana D, Vlachova Z, Cwiertka K, Kalita O, Melichar B. Radiotherapy management of brain metastases using conventional linear accelerator. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:412–416. PubMed

Vrána D, Študentová H, Matzenauer M, Vlachová Z, Cwierka K, Gremlica D, Kalita O. Treatment of brain metastases of renal cell cancer with combined hypofractionated stereotactic radiotherapy and whole brain radiotherapy with hippocampal sparing. Oncology Lett. 2016;11:3777–3781. PubMed PMC

Santeufemia DA, Tumolo S, De Paoli A, Lo Re G, Boz G, Miolo GM, Baresic T, Basso SM, Innocente R. Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esophageal carcinoma following trimodality therapy: A case report. Tumori. 2012;98:143e–145e. PubMed

Russo JK, Rosen L. TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: A case report. Tumori. 2011;97:406–410. PubMed

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer